本帖最后由 老马 于 2013-3-13 13:43 编辑 % ^) B- Y! `2 e/ A9 W0 o
1 N5 d' `3 @% o0 V+ f/ Z健择(吉西他滨)+顺铂+阿瓦斯汀
* S, i% B* Q& S& X" k" N7 B Gemzar +Cisplatin + Avastin! u; K& k* }! O( `9 G6 n- W
http://annonc.oxfordjournals.org/content/21/9/1804.full
% l3 @! F/ Y) D+ MOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& b# t2 K: F3 UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" K# z: O5 A& K1 KResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. $ U( @8 i5 X- z) x- r
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 232)
# D$ m* B# [! O% y' A华为网盘附件:
. u4 |2 d/ f1 p) ?% d+ U+ L【华为网盘】ava.JPG2 o2 _0 N2 }! V" ?
|